Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir

Brooks KM, Castillo-Mancilla JR, Morrow M, et al. Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. J Antimicrob Chemother. 2020;75(11):3303-3310.

Publication Type:

Journal Article

Authors:

Brooks, KM; JR Castillo-Mancilla; Morrow, M; et, al

Source:

J Antimicrob Chemother, Volume 75, Issue 11, p.3303-3310 (2020)

Cited On:

Patients With HIV/HCV Coinfection

Export Citation:

RIS Format

Top